136 related articles for article (PubMed ID: 14529481)
1. The discovery of NVP-LAQ824: from concept to clinic.
Remiszewski SW
Curr Med Chem; 2003 Nov; 10(22):2393-402. PubMed ID: 14529481
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
Remiszewski SW; Sambucetti LC; Atadja P; Bair KW; Cornell WD; Green MA; Howell KL; Jung M; Kwon P; Trogani N; Walker H
J Med Chem; 2002 Feb; 45(4):753-7. PubMed ID: 11831887
[TBL] [Abstract][Full Text] [Related]
3. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
Remiszewski SW; Sambucetti LC; Bair KW; Bontempo J; Cesarz D; Chandramouli N; Chen R; Cheung M; Cornell-Kennon S; Dean K; Diamantidis G; France D; Green MA; Howell KL; Kashi R; Kwon P; Lassota P; Martin MS; Mou Y; Perez LB; Sharma S; Smith T; Sorensen E; Taplin F; Trogani N; Versace R; Walker H; Weltchek-Engler S; Wood A; Wu A; Atadja P
J Med Chem; 2003 Oct; 46(21):4609-24. PubMed ID: 14521422
[TBL] [Abstract][Full Text] [Related]
4. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824.
Atadja P; Hsu M; Kwon P; Trogani N; Bhalla K; Remiszewski S
Novartis Found Symp; 2004; 259():249-66; discussion 266-8, 285-8. PubMed ID: 15171259
[TBL] [Abstract][Full Text] [Related]
5. Non-hydroxamate histone deacetylase inhibitors.
Suzuki T; Miyata N
Curr Med Chem; 2005; 12(24):2867-80. PubMed ID: 16305476
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors: the Abbott experience.
Curtin M; Glaser K
Curr Med Chem; 2003 Nov; 10(22):2373-92. PubMed ID: 14529480
[TBL] [Abstract][Full Text] [Related]
8. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.
Woo SH; Frechette S; Abou Khalil E; Bouchain G; Vaisburg A; Bernstein N; Moradei O; Leit S; Allan M; Fournel M; Trachy-Bourget MC; Li Z; Besterman JM; Delorme D
J Med Chem; 2002 Jun; 45(13):2877-85. PubMed ID: 12061890
[TBL] [Abstract][Full Text] [Related]
9. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.
Atadja P; Gao L; Kwon P; Trogani N; Walker H; Hsu M; Yeleswarapu L; Chandramouli N; Perez L; Versace R; Wu A; Sambucetti L; Lassota P; Cohen D; Bair K; Wood A; Remiszewski S
Cancer Res; 2004 Jan; 64(2):689-95. PubMed ID: 14744786
[TBL] [Abstract][Full Text] [Related]
10. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
Charrier C; Bertrand P; Gesson JP; Roche J
Bioorg Med Chem Lett; 2006 Oct; 16(20):5339-44. PubMed ID: 16904890
[TBL] [Abstract][Full Text] [Related]
12. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation.
Bouchain G; Delorme D
Curr Med Chem; 2003 Nov; 10(22):2359-72. PubMed ID: 14529479
[TBL] [Abstract][Full Text] [Related]
13. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
16. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Catley L; Weisberg E; Tai YT; Atadja P; Remiszewski S; Hideshima T; Mitsiades N; Shringarpure R; LeBlanc R; Chauhan D; Munshi NC; Schlossman R; Richardson P; Griffin J; Anderson KC
Blood; 2003 Oct; 102(7):2615-22. PubMed ID: 12816865
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
Guandalini L; Cellai C; Laurenzana A; Scapecchi S; Paoletti F; Romanelli MN
Bioorg Med Chem Lett; 2008 Sep; 18(18):5071-4. PubMed ID: 18723349
[TBL] [Abstract][Full Text] [Related]
18. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
Liao V; Liu T; Codd R
Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
[TBL] [Abstract][Full Text] [Related]
19. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
[TBL] [Abstract][Full Text] [Related]
20. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.
Haefner M; Bluethner T; Niederhagen M; Moebius C; Wittekind C; Mossner J; Caca K; Wiedmann M
World J Gastroenterol; 2008 Jun; 14(23):3681-92. PubMed ID: 18595135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
